TLR4 agonists as immunomodulatory agents

Abstract

Monophosphoryl lipid A (MPL^®) is a potent vaccine adjuvant derived from Salmonella minnesota that was recently licensed in Europe as a component of an improved vaccine for hepatitis B (Fendrix^®). MPL, like lipopolysaccharide from which it is derived, signals via the TLR4/MD-2 complex. We have produced a series of synthetic Toll-like receptor 4 (TLR4) agonists that are based upon the structure of the major hexa-acylated congener contained within MPL. These TLR4 agonists, termed the aminoalkyl glucosaminide phosphates (AGPs), stimulate the production of various cytokines by human peripheral blood mononuclear cells in vitro and up-regulate cell surface markers on monocytes, NK cells and B cells. In addition, AGPs provide non-specific resistance to challenge with viral and bacterial pathogens when administered to the upper airways of mice. Structure—activity relationship studies have shown that the activation of innate immune effectors by AGPs depends primarily on the length of the secondary acyl chains and the nature of the functional group attached to the aglycon component. Moreover, AGPs can act as potent adjuvants for mucosal administration of vaccine antigens, enhancing both antigen-specific antibody and cell-mediated immune responses. Thus, by combining the adjuvant and non-specific resistance induction properties of AGPs it may be possible to generate mucosal vaccines that provide innate protection immediately following administration together with long-term acquired immunity.

Keywords

TLR4 agonists immunomodulation aminoalkyl glucosaminide phosphates

References

Akira S. Mammalian Toll-like receptors. Curr Opin Immunol 2003; 15: 5—11.

Poltorak A. , He X. , Smirnova I. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282: 2085—2088.

Miyake K. Innate recognition of lipopolysaccharide by Toll-like receptor 4-MD—2 . Trends Microbiol 2004; 12: 186—192.

Berger FM The effect of endotoxin on resistance to infection and disease. Adv Pharmacol 1967; 5: 19—46.

Neter E. Endotoxins and the immune response. Curr Top Microbiol Immunol 1969; 47: 82—124.

Myers KR , Truchot AT , Ward J. , Hudson Y. , Ulrich JT A critical determinant of lipid A endotoxic activity. In: Nowotny A , Spitzer JJ , Ziegler EJ. (eds) Cellular and Molecular Aspects of Endotoxin Reactions. Amsterdam: Elsevier, 1990; 145—156.

Thoelen S. , Van Damme P , Mathei C. et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 1998 ; 16: 708—714.

Johnson DA , Sowell CG , Johnson CL et al. Synthesis and biological evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide 4-phosphates (AGPs). Bioorg Med Chem Lett 1999; 9: 2273—2278.

Cluff CW , Baldridge JR , Stöver AG et al. Synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect Immun 2005 ; 73: 3044—3052.

10.

Skeiky Yaw , Alderson MR , Ovendale PJ et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 2004; 172: 7618—7628.

11.

Varga SM , Wissinger EL , Braciale TJ The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses . J Immunol 2000; 165: 6487—6495.

12.

Kulkarni AB , Collins PL , Bacik I. et al. Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus. J Virol 1995; 69: 1261—1264.

13.

Stöver AG , Da Silva Correia J. , Evans JT et al. Structure—activity relationship of synthetic Toll-like receptor 4 agonists. J Biol Chem 2005; 279: 4440—4449.

14.

Probst P. , Skeiky YA , Steeves M. , Gervassi A. , Grabstein KH , Reed SG A Leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor-alpha production and expression of B7-1 in human monocyte-derived antigen-presenting cells. Eur J Immunol 1997; 27: 2634—2642.

15.

Collins PL , Chanock RM , Murphy BR Respiratory syncytial virus. In: Knipe DM , Howley PM. (eds) Field's Virology. Philadelphia, USA: Lippincott Williams & Wilkins, 2001; 21443—21486.

16.

Rohde G. , Wiethege A. , Borg I. et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalization: a case-control study. Thorax 2003; 58: 37—42.

17.

Malmgaard L. Induction and regulation of IFNs during viral infections . J Interferon Cytokine Res 2004; 24: 439—454.

18.

Takeda K. , Akira S. TLR signaling pathways. Semin Immunol 2004 ; 16: 3—9.

19.

Hoebe K. , Beutler B. LPS, dsRNA and the interferon bridge to adaptive immune responses: Trif, Tram, and other TIR adaptor proteins. J Endotoxin Res 2004; 10: 130—136.

20.

Ahmad A. , Alvarez F. Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis . J Leukoc Biol 2004; 76: 743—759.

21.

Baldridge JR , McGowan P. , Evans JT et al. Taking a toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 2004; 4: 1129—1138.

22.

Goodier MR , Londei M. Lipopolysaccharide stimulates the proliferation of human CD56+CD3— NK cells: a regulatory role of monocytes and IL-10. J Immunol 2000; 165: 139—147.

23.

Gerosa F. , Baldani-Guerra B. , Nisii C. , Marchesini V. , Carra G. , Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002; 195: 327—333.

24.

Fort MM , Mozaffarian A. , Stover AG et al. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J Immunol 2005; 174: 6416—6423.